Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Aytu Biopharma (AYTU) over the last 16 years, with Q4 2025 value amounting to -$6.3 million.

  • Aytu Biopharma's Cash from Financing Activities fell 12692.03% to -$6.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $13.3 million, marking a year-over-year increase of 540876.49%. This contributed to the annual value of $15.4 million for FY2025, which is 132369.26% up from last year.
  • As of Q4 2025, Aytu Biopharma's Cash from Financing Activities stood at -$6.3 million, which was down 12692.03% from $2.3 million recorded in Q3 2025.
  • In the past 5 years, Aytu Biopharma's Cash from Financing Activities ranged from a high of $13.6 million in Q3 2022 and a low of -$6.4 million during Q1 2021
  • Its 5-year average for Cash from Financing Activities is $1.3 million, with a median of $720500.0 in 2024.
  • As far as peak fluctuations go, Aytu Biopharma's Cash from Financing Activities plummeted by 209047.62% in 2024, and later skyrocketed by 111657.3% in 2025.
  • Aytu Biopharma's Cash from Financing Activities (Quarter) stood at $6.6 million in 2021, then crashed by 128.3% to -$1.9 million in 2022, then skyrocketed by 93.24% to -$126000.0 in 2023, then plummeted by 2090.48% to -$2.8 million in 2024, then crashed by 126.92% to -$6.3 million in 2025.
  • Its Cash from Financing Activities stands at -$6.3 million for Q4 2025, versus $2.3 million for Q3 2025 and $13.0 million for Q2 2025.